Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone disease after kidney transplantation.

Stuart M Sprague1, Michelle A Josephson

  • 1Division of Nephrology and Hypertension, Evanston Northwestern Healthcare, Feinberg School of Medicine, Northwestern University, Evanston, IL 60201, USA. ssprague@northwestern.edu

Seminars in Nephrology
|January 20, 2004
PubMed
Summary

Kidney transplant recipients face significant bone disease and fracture risks due to rapid bone loss post-transplant. Immunosuppression, particularly glucocorticoids and calcineurin inhibitors, significantly impacts bone health.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Prior Adverse Pregnancy Outcome on Kidney Structure and Function in Kidney Donors.

Kidney360·2026
Same author

Elevations in Donor-Derived Cell-Free DNA and Allograft Outcomes in Kidney Transplantation.

Journal of the American Society of Nephrology : JASN·2026
Same author

Correction to: Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.

Kidney360·2026
Same author

Is the Current Practice of Out-of-Sequence Kidney Allocation Justified? Assessing Outcomes, Utility, Efficiency, and Equity.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Pregnancy, Where Assisted Reproductive Technology and Transplant Science Intersect.

Transplantation·2025
Same author

Managing Dysregulated Vitamin D Metabolism in CKD: Time to Update Conventional Wisdom?

Kidney360·2025

Area of Science:

  • Nephrology
  • Endocrinology
  • Orthopedics

Background:

  • Kidney transplantation is the preferred treatment for end-stage kidney disease.
  • Post-transplant bone disease is a common complication, worsening pre-existing metabolic bone issues.
  • Rapid bone loss occurs within 3-6 months, increasing fracture risk.

Purpose of the Study:

  • To review the pathophysiology, clinical presentation, and management of post-transplant bone disease.
  • To highlight the impact of immunosuppressive medications on bone metabolism.
  • To emphasize the importance of evaluating and managing bone health in kidney transplant recipients.

Main Methods:

  • Review of existing literature on post-transplant bone disease.
  • Analysis of factors contributing to bone loss and fracture risk.

Related Experiment Videos

  • Discussion of the role of immunosuppressive agents in bone complications.

    • Main Results:

    • Fracture risk ranges from 5% to 44%, with peripheral fractures being more common.
    • Diabetes mellitus increases fracture risk.
    • Parathyroid hormone and osteocalcin levels typically decrease post-transplant; other biomarkers are unpredictable.
    • Immunosuppressants like glucocorticoids and calcineurin inhibitors significantly affect bone turnover.

    Conclusions:

    • Post-transplant bone disease is a critical complication requiring careful management.
    • Immunosuppressive therapy is a major driver of bone disorders.
    • Comprehensive evaluation and management of bone health are essential components of post-transplant care.